SNNAQ.US Sienna Biopharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 18, 2026
0.0001 0.0001
Market cap
USD 3.09K
P/E
-
P/B
0.00x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is SNNAQ.US undervalued?

Graham number

The Graham number of Sienna Biopharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sienna Biopharmaceuticals Inc fundamental analysis

No fundamental analysis for Sienna Biopharmaceuticals Inc yet.

Sienna Biopharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sienna Biopharmaceuticals Inc

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a top…

Full company profile